Gapping down
In reaction to disappointing earnings/guidance: CIDM -24.1%, SCS -8.3%, BBBY -7.7%, MLHR -5.8%, CACI -4.6%, FUL -3.5%, FUL -3.5%, PM -2.4%, .
M&A news: RDEN -8.9% (reports that LG is no longer interested in the company).
Select EU financial related names showing weakness: BCS -4.8% (confirms fraud charges against Barclays in connection with marketing and operation of its dark pool), CS -2.9%, DB -2.8%, ING -1.9%, HSBC -1%.
Select metals/mining stocks trading lower: HL -1.8%, GG -1.7%, IAG -1.5%, HMY -1.4%, SLW -1.2%, GOLD -1.1%, GDX -0.8%, NEM -0.8%, SLV -0.4%.
Other news: KPTI -2.3% (announces proposed public offering of 2.2 mln shares of common stock; consist of 2,000,000 shares to be offered by Karyopharm and 200,000 shares to be offered by existing stockholders), BRX -1.6% (prices 29,950,000 shares of common stock at $22.50 per share), STM -1.5% (announces a $1 bln dual-tranche offering of Convertible Bonds and the launch of a share buy-back program), MRD -1% (priced private placement to eligible purchasers of $600 mln in aggregate principal amount of 5.875% senior unsecured notes due 2022 at par).
Analyst comments: XRX -1.6% (downgraded at Argus), EL -0.7% (downgraded to Neutral from Buy at B. Riley & Co), NFLX -0.6% (initiated with a Underweight at Barclays), UAL -0.5% (downgraded to In-line from Outperform at Imperial Capital).
In reaction to disappointing earnings/guidance: CIDM -24.1%, SCS -8.3%, BBBY -7.7%, MLHR -5.8%, CACI -4.6%, FUL -3.5%, FUL -3.5%, PM -2.4%, .
M&A news: RDEN -8.9% (reports that LG is no longer interested in the company).
Select EU financial related names showing weakness: BCS -4.8% (confirms fraud charges against Barclays in connection with marketing and operation of its dark pool), CS -2.9%, DB -2.8%, ING -1.9%, HSBC -1%.
Select metals/mining stocks trading lower: HL -1.8%, GG -1.7%, IAG -1.5%, HMY -1.4%, SLW -1.2%, GOLD -1.1%, GDX -0.8%, NEM -0.8%, SLV -0.4%.
Other news: KPTI -2.3% (announces proposed public offering of 2.2 mln shares of common stock; consist of 2,000,000 shares to be offered by Karyopharm and 200,000 shares to be offered by existing stockholders), BRX -1.6% (prices 29,950,000 shares of common stock at $22.50 per share), STM -1.5% (announces a $1 bln dual-tranche offering of Convertible Bonds and the launch of a share buy-back program), MRD -1% (priced private placement to eligible purchasers of $600 mln in aggregate principal amount of 5.875% senior unsecured notes due 2022 at par).
Analyst comments: XRX -1.6% (downgraded at Argus), EL -0.7% (downgraded to Neutral from Buy at B. Riley & Co), NFLX -0.6% (initiated with a Underweight at Barclays), UAL -0.5% (downgraded to In-line from Outperform at Imperial Capital).